Connecting the Dots Between Prime, CI/ESI, and WBA

In a great example of Nephron’s more timely AND deeper research product, Eric Percher and Nephron’s Drug Supply Chain team published a notable “double feature” last week:  While working on the deep dive of Prime+Cigna/ESI it became clear that ESI is also in the process of moving generic sourcing in-house from WBAD.

The upshot is yet another headwind for WBAD for 2HFY20 alongside the re-cut Prime network agreement.  Nephron subscribers were treated to a WBA note focused on the withdrawl from WBAD as well as a CI note more focused on the Ascent Contracting & Econdisc Sourcing GPOs. for more information.